Lupin announces achievement of key milestones for its clinical stage MEK inhibitor compound

Lupin’s MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers

Lupin announced the achievement of key milestones for Lupin’s MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers.

As part of the agreement, Lupin has received payment of $50 million from Boehringer Ingelheim for the achievement of key milestones.

Lupin and Boehringer Ingelheim inked a licensing, development and commercialization agreement in 2019 for Lupin’s novel oncology compound to treat KRAS-driven cancers. Lupin’s MEK inhibitor developed as part of its oncology pipeline had previously shown preclinical activity as a single agent as well as in combination.

Boehringer IngelheimKRAS-driven cancersLupinMEK inhibitor compoundnovel oncology compound
Comments (0)
Add Comment